Please assess the completion status of the following clinical trial:

Trial Title: Phase I Study to Compare the Pharmacokinetics, Pharmacodynamics, and Safety Between CT-P41 and US-licensed Prolia in Healthy Male Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy male subject, between the ages of 28 and 55 years, both inclusive~2. Subject had a body mass index (BMI) between 18.5 and 29.9 kg/m2, both inclusive, and a body weight between 50.0 and 99.9 kg, both inclusive, when rounded to the nearest tenth.~3. Subject with total serum calcium ≥ 8.5 mg/dL (≥ 2.125 mmol/L) and serum 25-OH vitamin D ≥ 20 ng/mL (≥ 50 nmol/L)~Exclusion Criteria:~1. Subject was a female.~2. Subject with a hypersensitivity to any component of denosumab or dry natural rubber (a derivative of latex).~3. Subject was confirmed or suspected with infection of coronavirus disease 2019 (COVID-19) at screening, or had had contact with COVID-19 patient within 14 days from screening.~4. Subject had a medical history of and/or current medical condition that can have effect on the study. Details to be discussed with investigator as per Protocol.~   1. Subjects with known risk factors for hypocalcaemia~  2. Subjects with known intolerance to calcium or vitamin D supplements~  3. Subjects with known infection with active hepatitis B, hepatitis C, human immunodeficiency virus, or syphilis~5. Subject had a history of and/or concurrent use of medications including any prior therapy that can have effect on the study. Details to be discussed with investigator as per Protocol.~6. Subjects have or had any therapy that might significantly affect bone metabolism

- Gender: MALE
- Minimum Age: 28 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- CT-P41 (Type: EXPERIMENTAL): a single 60 mg subcutaneous (SC) injection via pre-filled syringe (PFS)
- US-licensed Prolia (Type: ACTIVE_COMPARATOR): a single 60 mg subcutaneous (SC) injection via pre-filled syringe (PFS)

Based on this trial design, predict the completion outcome and termination type (if applicable).